Adagio Medical Holdings, Inc. received a deficiency letter from Nasdaq on August 13, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The company reported negative stockholders' equity of $(415,000) as of June 30, 2026, and lacks alternative quantitative standards for continued listing. Nasdaq has provided a 45-day compliance period ending September 28, 2026, to submit a plan to regain compliance, with potential for an additional 180-day extension if the plan is accepted. The company intends to monitor its equity position and evaluate options to restore compliance while addressing liquidity concerns. Adagio Medical Holdings operates in the medical device industry, developing minimally invasive treatments for cardiovascular disease.

Adagio Medical Holdings reported a net loss of $6.7 million, or $(0.30) per share, for the quarter ended June 30, 2026, compared to a $3.9 million loss in the prior year period. Cash and cash equivalents stood at $7.7 million as of June 30, 2026. The company announced pivotal results from its 209-patient FULCRUM-VT trial, demonstrating an 84% freedom from ICD shock at six months and a promising safety profile with only 2.4% major adverse events. Adagio also submitted a Premarket Approval application to the FDA for its vCLAS Ventricular Ablation System and treated the first patient in Europe using its next-generation vCLAS Ultra catheter under Expanded Access authorization. The company operates in the medical device industry, developing and commercializing catheter ablation technologies for cardiac arrhythmias.

Adagio Medical Holdings, Inc. received a notice from Nasdaq on June 12, 2026, stating its common stock is not in compliance with the Minimum Bid Price Requirement. The company's stock price fell below $1.00 per share for 30 consecutive business days. Adagio has 180 days, until December 9, 2026, to regain compliance by maintaining a closing price of at least $1.00 for ten consecutive trading days. Failure to comply may lead to a second 180-day period involving a potential reverse stock split or eventual delisting. The company is evaluating options to meet listing standards. Adagio Medical Holdings, Inc. is a medical technology company.